Loading clinical trials...
Loading clinical trials...
An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria
Conditions
Interventions
AK002
Locations
4
United States
Allakos Investigational Site
Edgewater, Florida, United States
Allakos Investigational Site
Cincinnati, Ohio, United States
Allakos Investigational Site
Berlin, Germany
Allakos Investigational Site
Mainz, Germany
Start Date
January 23, 2018
Primary Completion Date
November 21, 2018
Completion Date
April 6, 2020
Last Updated
March 4, 2024
NCT04774315
NCT06063044
NCT04584190
NCT02000648
NCT02047136
NCT02435238
Lead Sponsor
Allakos Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions